ClassID:

21218

A61K2039/605 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen; Proteins MHC molecules or ligands thereof

Recent Application in this class:
#1
20260130978
2026-05-14

Ultrapurified Phospholipoproteomic Composition for High-Purity Biomolecular Research and Precision Therapeutics

#2
20260116941
2026-04-30

MODIFIED MAMMALIAN VESICLES AND COMPOSITIONS AND METHODS RELATED THERETO

#3
20260116918
2026-04-30

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

#4
20260097105
2026-04-09

SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS

#5
20260041755
2026-02-12

ALPHAVIRUS T CELL EPITOPES, MEGAPOOLS AND USES THEREOF

#6
20260041747
2026-02-12

T CELL EPITOPES ASSOCIATED WITH TYPE 1 DIABETES

#7
20250382335
2025-12-18

Panel comprising Borrelia MHC multimers

#8
20250319173
2025-10-16

LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST

#9
20250295746
2025-09-25

THERAPEUTIC RNA FOR LUNG CANCER

#10
20250270284
2025-08-28

MHC Class II Protein Constructs

#11
20250269000
2025-08-28

ANTI-TUMOUR RESPONSES TO CYTOKERATINS

#12
20250262293
2025-08-21

THERAPEUTIC RNA FOR HPV-POSITIVE CANCER

#13
20250262288
2025-08-21

Cellular Adjuvants for Viral Infection

#14
20250249084
2025-08-07

ALPHAVIRUS ANTIGEN VECTORS

#15
20250249039
2025-08-07

PRAME IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING PRAME IMMUNOGENIC PEPTIDES, AND USES THEREOF

#16
20250242005
2025-07-31

T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof

#17
20250222083
2025-07-10

MHC IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE

#18
20250213679
2025-07-03

POLYNUCLEOTIDE VACCINES AND METHODS OF USING THE SAME

#19
20250205323
2025-06-26

MHC IB-MEDIATED ISLET-ANTIGEN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR TYPE 1 DIABETES

#20
20250205322
2025-06-26

MHC IB-MEDIATED AQUAPORIN 4 (AQP4)-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR NMO

#21
20250205321
2025-06-26

MHC IB-MEDIATED ALPHA-SYNUCLEIN-SPECIFIC TOLERANCE INDUCTION AS A NOVEL TREATMENT FOR PARKINSON'S DISEASE

#22
20250179143
2025-06-05

SYSTEMS AND METHODS FOR CHAPERONE-MEDIATED LIGAND EXCHANGE ON MHC-I AND MHC-RELATED MOLECULES USING CHICKEN TAPBPR

#23
20250145684
2025-05-08

IMMUNOTHERAPY WITH B*08 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS

#24
20250121043
2025-04-17

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

#25
20250051420
2025-02-13

RECOMBINANT pMHC CLASS II MOLECULES

#26
20250041404
2025-02-06

T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof

#27
20250041396
2025-02-06

T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof

#28
20250025544
2025-01-23

IMMUNE CHECKPOINT INHIBITOR CO-EXPRESSION VECTORS

#29
20240382606
2024-11-21

NANOPARTICLES FOR ANTIGEN-SPECIFIC CELL PROGRAMMING AND USES THEREOF

#30
20240350603
2024-10-24

Method Of Validating The Triggering Of An Immune Response To A Neoepitope Of A Tumor With T-Cells

#31
20240342262
2024-10-17

Cellular Adjuvants for Viral Infection

#32
20240299521
2024-09-12

Cellular Adjuvants for Viral Infection

#33
20240299515
2024-09-12

MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

#34
20240201171
2024-06-20

ASSAY TO MEASURE THE POTENCY OF RECEPTOR-LIGAND INTERACTIONS IN NANOMEDICINES

#35
20240139298
2024-05-02

MHC CLASS II T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF

#36
20240082411
2024-03-14

T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof

#37
20240067700
2024-02-29

T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF

#38
20240067679
2024-02-29

SARS-COV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME

#39
20240024445
2024-01-25

Alphavirus neoantigen vectors

#40
20240024438
2024-01-25

METHODS AND COMPOSITIONS COMPRISING MHC CLASS PEPTIDES

#41
20230416338
2023-12-28

COMBINATIONS OF MHC CLASS IB MOLECULES AND PEPTIDES FOR TARGETED THERAPEUTIC IMMUNOMODULATION

#42
20230405100
2023-12-21

VACCINE

#43
20230346900
2023-11-02

MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof

#44
20230338530
2023-10-26

COMPOSITION COMPRISING ANTIGEN-PRESENTING CELL CO-EXPRESSING MHC AND TUMOR ANTIGEN, AND CANCER TREATMENT USING SAME

#45
20230338509
2023-10-26

T CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF

#46
20230330215
2023-10-19

SARS-COV-2 VACCINES

#47
20230330197
2023-10-19

MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

#48
20230310562
2023-10-05

Antigen presenting scaffolds for immune-cell manipulation

#49
20230227530
2023-07-20

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

#50
20230218731
2023-07-13

Antigen Presenting Polypeptide Complexes and Methods of Use Thereof

#51
20230201335
2023-06-29

Antigen Presenting Polypeptide Complexes and Methods of Use Thereof

#52
20230190901
2023-06-22

PEPTIDES DERIVED FROM MELANOMA-ASSOCIATED ANTIGEN C2 (MAGEC2) AND USES THEREOF

#53
20230190898
2023-06-22

INDIVIDUALIZED VACCINES FOR CANCER

#54
20230134801
2023-05-04

MHC RESTRICTED IMMUNOGENIC TELOMERASE REVERSE TRANSCRIPTASE -SPECIFIC PEPTIDES, THEIR COMPLEX CONJUGATES, AND METHODS OF USING THE SAME

#55
20230129352
2023-04-27

MHC class I associated peptides for prevention and treatment of zika virus

#56
20230117521
2023-04-20

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF

#57
20220401534
2022-12-22

METHODS AND COMPOSITIONS FOR SUSTAINED IMMUNOTHERAPY

#58
20220387583
2022-12-08

RECOMBINANT PMHC MOLECULES

#59
20220370587
2022-11-24

Cellular adjuvants for viral infection

#60
20220293215
2022-09-15

SYSTEMS AND METHODS FOR MHC CLASS II EPITOPE PREDICTION

#61
20220288177
2022-09-15

PRODUCTION OF MHC II/CII COMPLEXES

#62
20220257740
2022-08-18

TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES

#63
20220257733
2022-08-18

ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF

#64
20220226453
2022-07-21

Alphavirus antigen vectors

#65
20220135645
2022-05-05

Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof

#66
20220111025
2022-04-14

Vaccine

#67
20220111024
2022-04-14

Vaccine

#68
20220105162
2022-04-07

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

#69
20220096614
2022-03-31

PEPTIDE-INDUCED NK CELL ACTIVATION

#70
20220064226
2022-03-03

Panel comprising MHC multimers

#71
20220031823
2022-02-03

PERSONALISED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM

#72
20220008472
2022-01-13

Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

#73
20220008471
2022-01-13

Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

#74
20210379169
2021-12-09

TELEOST INVARIANT CHAIN CANCER VACCINE

#75
20210347822
2021-11-11

Immunotherapy against several tumors including neuronal and brain tumors

#76
20210322528
2021-10-21

PEPTIDES FROM NPSR1

#77
20210261614
2021-08-26

Immunotherapy against several tumors including neuronal and brain tumors

#78
20210253637
2021-08-19

Immunotherapy against several tumors including neuronal and brain tumors

#79
20210238227
2021-08-05

Immunotherapy against several tumors including neuronal and brain tumors

#80
20210230633
2021-07-29

NUCLEOTIDE VACCINE

#81
20210213122
2021-07-15

IMMUNE CHECKPOINT INHIBITOR CO-EXPRESSION VECTORS

#82
20210205470
2021-07-08

METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS

#83
20210198649
2021-07-01

NOVEL NUCLEIC ACID MOLECULES

#84
20210145949
2021-05-20

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

#85
20210138054
2021-05-13

PEPTIDES DERIVED FROM PROSTATE SPECIFIC ANTIGEN (KLK3) AND COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES

#86
20210121551
2021-04-29

PEPTIDES DERIVED FROM MELANOMA-ASSOCIATED ANTIGEN C2 (MAGEC2) AND USES THEREOF

#87
20210121547
2021-04-29

PROGESTERONE-ASSOCIATED ENDOMETRIAL PROTEIN (PAEP) AND USES THEREOF

#88
20210113672
2021-04-22

Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells

#89
20210106677
2021-04-15

VACCINE DEVELOPMENT METHODOLOGY BASED ON AN ADHESION MOLECULE

#90
20210061857
2021-03-04

PEPTIDES FROM PIWIL1

#91
20210047629
2021-02-18

PEPTIDES DERIVED FROM KALLIKREIN 4

#92
20210017228
2021-01-21

PEPTIDES

#93
20200390856
2020-12-17

METHODS OF TREATING AUTOIMMUNE DISEASE

#94
20200345855
2020-11-05

Compositions and methods for immunotherapy

#95
20200268871
2020-08-27

MHC class I associated peptides for prevention and treatment of zika virus

#96
20200246455
2020-08-06

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#97
20200197500
2020-06-25

Alphavirus neoantigen vectors

#98
20200188438
2020-06-18

Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods

#99
20200157175
2020-05-21

COMBINATIONS OF MHC CLASS IB MOLECULES AND PEPTIDES FOR TARGETED THERAPEUTIC IMMUNOMODULATION

#100
20200109160
2020-04-09

Lipid A mimics, methods of preparation, and uses thereof

#101
20200103407
2020-04-02

Method for the detection, preparation and depletion of CD4+ t lymphocytes

#102
20200101169
2020-04-02

Antigen-specific tolerance and compositions for induction of same

#103
20200101149
2020-04-02

Cellular adjuvants for viral infection

#104
20200095546
2020-03-26

Nanoscale artificial antigen presenting cells

#105
20200085927
2020-03-19

Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif

#106
20200057048
2020-02-20

ASSAY TO MEASURE THE POTENCY OF RECEPTOR-LIGAND INTERACTIONS IN NANOMEDICINES

#107
20200055918
2020-02-20

NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF

#108
20200009265
2020-01-09

Methods and compositions for treating multiple sclerosis and related disorders

#109
20200009238
2020-01-09

ENGINEERED INVARIANT CHAIN MOLECULE FOR IMPROVED MHC CLASS I LOADING

#110
20190338014
2019-11-07

Fusion peptides with antigens linked to short fragments of invariant chain(CD74)

#111
20190336589
2019-11-07

IMMUNIZING PEPTIDE, METHOD FOR PRODUCING IMMUNIZING PEPTIDE, PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE CONTAINING SAME, AND METHOD FOR TREATING IMMUNE DISEASE

#112
20190328854
2019-10-31

C5 IMMUNIZATION FOR AUTOLOGOUS ANTI-C5 ANTIBODY PRODUCTION

#113
20190322731
2019-10-24

Molecular Complex for Targeting Antigens Towards Cells Comprising Antigens and Uses Thereof for Vaccination

#114
20190316069
2019-10-17

Antigen presenting scaffolds for immune-cell manipulation

#115
20190240302
2019-08-08

Vaccine

#116
20190216907
2019-07-18

COMPOSITIONS FOR AND METHODS OF TREATING AND PREVENTING CANCER TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS

#117
20190083593
2019-03-21

Individualized vaccines for cancer

#118
20190083591
2019-03-21

PEPTIDES

#119
20190070275
2019-03-07

NEOANTIGEN COMPOSITIONS AND METHODS OF USING THE SAME IN IMMUNOONCOTHERAPY

#120
20190060427
2019-02-28

Methods and compositions for sustained immunotherapy

#121
20190040378
2019-02-07

Nucleic acid molecules

#122
20190010190
2019-01-10

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

#123
20190002523
2019-01-03

T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex

#124
20180346606
2018-12-06

Reversible protein multimers, methods for their production and use

#125
20180339028
2018-11-29

PEPTIDES

#126
20180339027
2018-11-29

PEPTIDES FROM NPSR1

#127
20180319863
2018-11-08

ANTI-HLA ASSAY AND METHODS

#128
20180243409
2018-08-30

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#129
20180214564
2018-08-02

COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

#130
20180201689
2018-07-19

Antibody Fusion Protein and Preparation Method and Use Thereof

#131
20180185508
2018-07-05

Antigen-specific tolerance and compositions for induction of same

#132
20180185507
2018-07-05

Compositions for generation of immune tolerance to specific antigens

#133
20180185505
2018-07-05

Compositions for inducing antigen-specific tolerance

#134
20180037621
2018-02-08

Compositions and methods for enhancing an immune response

#135
20180009833
2018-01-11

Lipid A mimics, methods of preparation, and uses thereof

#136
20170333540
2017-11-23

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

#137
20170312348
2017-11-02

Methods and compositions for treating multiple sclerosis and related disorders

#138
20170298328
2017-10-19

Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

#139
20170281752
2017-10-05

Antigen delivery system

#140
20170196957
2017-07-13

RECOMBINANT T CELL RECEPTOR LIGAND COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CANCER

#141
20170184612
2017-06-29

USE OF LEUKOCYTES AND NOVEL BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION, AND TREATMENT OF A NEUROLOGICAL DISORDER

#142
20170106081
2017-04-20

Cellular vaccine and method of inducing an immune response in a subject

#143
20170106066
2017-04-20

ENGINEERED INVARIANT CHAIN MOLECULE FOR IMPROVED MHC CLASS I LOADING

#144
20160376317
2016-12-29

Immunotherapy against several tumors including neuronal and brain tumors

#145
20160376316
2016-12-29

Immunotherapy against several tumors including neuronal and brain tumors

#146
20160376315
2016-12-29

Immunotherapy against several tumors including neuronal and brain tumors

#147
20160376314
2016-12-29

Immunotherapy against several tumors including neuronal and brain tumors

#148
20160376313
2016-12-29

Immunotherapy against several tumors including neuronal and brain tumors

#149
20160376312
2016-12-29

Immunotherapy against several tumors including neuronal and brain tumors

#150
20160361431
2016-12-15

Methods for reducing immune responses

#151
20160355550
2016-12-08

Immunotherapy against several tumors including neuronal and brain tumors

#152
20160354484
2016-12-08

Compositions for inducing antigen-specific tolerance

#153
20160354454
2016-12-08

Methods for induction of antigen-specific immune tolerance

#154
20160354453
2016-12-08

Compositions for generating immune tolerance by targeting erythrocytes

#155
20160271237
2016-09-22

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

#156
20160193316
2016-07-07

Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid Compositions

#157
20160184415
2016-06-30

Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens

#158
20160158151
2016-06-09

On demand vesicle formation from vesicle precursors suitable for long-term storage

#159
20160129133
2016-05-12

COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

#160
20160058853
2016-03-03

Individualized vaccines for cancer

#161
20160051698
2016-02-25

Nanoscale artificial antigen presenting cells

#162
20160045594
2016-02-18

DIRECTED IMMUNE STIMULATION

#163
20160000906
2016-01-07

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#164
20150343055
2015-12-03

Compositions and methods using recombinant MHC molecules for the treatment of stroke

#165
20150273039
2015-10-01

Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof

#166
20150250871
2015-09-10

METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS

#167
20150231216
2015-08-20

Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif

#168
20150216966
2015-08-06

Cellular vaccine and method of inducing an immune response in a subject

#169
20150209446
2015-07-30

Methods and compositions for treating multiple sclerosis and related disorders

#170
20150125536
2015-05-07

Methods and compositions for sustained immunotherapy

#171
20150125478
2015-05-07

Immunotherapy against several tumors including neuronal and brain tumors

#172
20150118253
2015-04-30

Methods and compositions for the treatment of cancer and infectious disease using alpha(2) macroglobulin-antigenic molecule complexes

#173
20150098956
2015-04-09

Recombinant polypeptides comprising MHC class II α1 domains

#174
20150037363
2015-02-05

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

#175
20140162293
2014-06-12

Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency

#176
20130289253
2013-10-31

Reversible protein multimers, methods for their production and use

#177
20130273087
2013-10-17

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

#178
20130195908
2013-08-01

Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination

#179
20130058869
2013-03-07

Prevention And Treatment Of Amyloidogenic Disease

#180
20130004456
2013-01-03

Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

#181
20120329670
2012-12-27

EPITOPE TESTING USING SOLUBLE HLA

#182
20120329080
2012-12-27

ANTI-HLA ASSAY AND METHODS

#183
20120328642
2012-12-27

Botulinum neurotoxin antigenic compositions and methods

#184
20120302452
2012-11-29

COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS

#185
20120301871
2012-11-29

COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS

#186
20120276127
2012-11-01

Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)

#187
20120276116
2012-11-01

Prevention and Treatment of Amyloidogenic Disease

#188
20120195921
2012-08-02

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

#189
20120178139
2012-07-12

Erythrocyte-binding therapeutics

#190
20120141517
2012-06-07

Immunotherapy against several tumors including neuronal and brain tumors

#191
20120141482
2012-06-07

MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES

#192
20120135029
2012-05-31

Method for the purification of protein complexes

#193
20120121577
2012-05-17

ANTIBODIES AS T CELL RECEPTOR MIMICS, METHODS OF PRODUCTION AND USES THEREOF

#194
20120034157
2012-02-09

Artificial cells

#195
20120034156
2012-02-09

Artificial cells

#196
20120034155
2012-02-09

Artificial cells

#197
20110306756
2011-12-15

Prevention and Treatment of Amyloidogenic Disease

#198
20110293623
2011-12-01

ANTIBODIES AS T CELL RECEPTOR MIMICS, METHODS OF PRODUCTION AND USES THEREOF

#199
20110243967
2011-10-06

MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES

#200
20110236411
2011-09-29

MHC multimers in tuberculosis diagnostics, vaccine and therapeutics

#201
20110217308
2011-09-08

Compositions and methods using recombinant MHC molecules for the treatment of stroke

#202
20110212131
2011-09-01

METHOD FOR ENHANCING AN IMMUNE RESPONSE

#203
20110092961
2011-04-21

Artificial cells

#204
20110070154
2011-03-24

Artificial cells

#205
20110070153
2011-03-24

Artificial cells

#206
20110065587
2011-03-17

EPITOPE TESTING USING SOLUBLE HLA

#207
20110061136
2011-03-10

Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof

#208
20110059121
2011-03-10

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS

#209
20110008382
2011-01-13

Compositions and methods using recombinant MHC molecules for the treatment of uveitis

#210
20110002963
2011-01-06

Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

#211
20100303894
2010-12-02

treatment

#212
20100278904
2010-11-04

NUCLEOTIDE VACCINE

#213
20100209452
2010-08-19

COMPOSITIONS COMPRISING AN ANTIGEN, AN AMPHIPATHIC COMPOUND AND A HYDROPHOBIC CARRIER, AND USES THEREOF

#214
20100158931
2010-06-24

Immunotherapy against several tumors including neuronal and brain tumors

#215
20100105107
2010-04-29

PURIFICATION AND CHARACTERIZATION OF SOLUBLE MHC PROTEINS

#216
20100080817
2010-04-01

Human papillomavirus / Ii-Key hybrids and methods of use

#217
20100068218
2010-03-18

Optimized multi-epitope constructs and uses thereof

#218
20100015597
2010-01-21

PRODUCTION OF BIOLOGICAL CARRIERS FOR INDUCTION OF IMMUNE RESPONSE AND INHIBITION OF VIRAL REPLICATION

#219
20100008920
2010-01-14

Reagents and Methods for Engaging Unique Clonotypic Lymphocyte Receptors

#220
20090324644
2009-12-31

CHIMERIC VACCINE ANTIGENS AGAINST THE AVIAN INFLUENZA VIRUS

#221
20090304679
2009-12-10

Antibodies as T cell receptor mimics, methods of production and uses thereof

#222
20090297511
2009-12-03

PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

#223
20090291493
2009-11-26

Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency

#224
20090239794
2009-09-24

HCV F PROTEIN AND USES THEREOF

#225
20090233318
2009-09-17

Methods of assaying vaccine potency

#226
20090232766
2009-09-17

Compositions for Inducing Immune Response Comprising Inverted Microsomes

#227
20090227516
2009-09-10

COMPOUND COMPRISING AN AUTOANTIGENIC PEPTIDE AND A CARRIER WITH A MHC BINDING MOTIF

#228
20090226474
2009-09-10

Antibodies as T cell receptor mimics, methods of production and uses thereof

#229
20090191231
2009-07-30

Prevention and treatment of amyloidogenic disease

#230
20090182131
2009-07-16

Methods for removing anti-MHC antibodies from a sample

#231
20090155292
2009-06-18

Compositions and methods for the prevention and treatment of autoimmune conditions

#232
20090117153
2009-05-07

Disulfide trap MHC class I molecules and uses therefor

#233
20090075304
2009-03-19

METHODS OF ASSAYING VACCINE POTENCY

#234
20090069544
2009-03-12

Humanized antibodies that recognize beta amyloid peptide

#235
20090042285
2009-02-12

Antibodies at T cell receptor mimics, methods of production and uses thereof

#236
20080281082
2008-11-13

HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE

#237
20080227719
2008-09-18

PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

#238
20080227718
2008-09-18

Prevention and treatment of amyloidogenic disease

#239
20080221306
2008-09-11

Humanized antibodies that recognize beta amyloid peptide

#240
20080187536
2008-08-07

Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity

#241
20080145872
2008-06-19

Expression of HLA proteins on non human cells

#242
20080096818
2008-04-24

PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

#243
20080095798
2008-04-24

Ii-key enhanced vaccine potency

#244
20080050367
2008-02-28

Humanized antibodies that recognize beta amyloid peptide

#245
20080032921
2008-02-07

Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions

#246
20080019988
2008-01-24

Targeting of genetic vaccine vectors

#247
20070280957
2007-12-06

Change of the Load State of Mhc Molecules

#248
20070184022
2007-08-09

Composition for inducing immune response comprising inverted microsomes

#249
20070099183
2007-05-03

Comparative ligand mapping from MHC positive cells

#250
20070092530
2007-04-26

Antibodies as T cell receptor mimics, methods of production and uses thereof

#251
20070048330
2007-03-01

Optimized multi-epitope constructs and uses thereof

#252
20060276629
2006-12-07

Purification and characterization of soluble human HLA proteins

#253
20060257431
2006-11-16

Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells

#254
20060240033
2006-10-26

Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease

#255
20060165710
2006-07-27

Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

#256
20060134126
2006-06-22

Peptide constructs for treating disease

#257
20060040310
2006-02-23

Epitope testing using soluble HLA

#258
20060034865
2006-02-16

Soluble MHC artificial antigen presenting cells

#259
20060034858
2006-02-16

Prevention and treatment of amyloidogenic disease

#260
20060034850
2006-02-16

Antibodies as T cell receptor mimics, methods of production and uses thereof

#261
20060029611
2006-02-09

Prevention and treatment of amyloidogenic disease

#262
20060013822
2006-01-19

Utilization of mhc class II binding motifs in immunization to produce immune, serum, monoclonal antibodies and vaccines

#263
20050260605
2005-11-24

Targeting of genetic vaccine vectors

#264
20050255122
2005-11-17

Prevention and treatment of amyloidogenic disease

#265
20050249727
2005-11-10

Prevention and treatment of amyloidogenic disease

#266
20050249725
2005-11-10

Humanized antibodies that recognize beta amyloid peptide

#267
20050196399
2005-09-08

Prevention and treatment of amyloidogenic disease

#268
20050191314
2005-09-01

Prevention and treatment of amyloidogenic disease

#269
20050191292
2005-09-01

Prevention and treatment of amyloidogenic disease

#270
20050164166
2005-07-28

Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency

#271
20050163788
2005-07-28

Prevention and treatment of amyloidogenic disease

#272
20050158336
2005-07-21

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#273
20050142132
2005-06-30

Prevention and treatment of amyloidogenic disease

#274
20050063979
2005-03-24

Antigen presenting vesicles

#275
20050059802
2005-03-17

Prevention and treatment of amyloidogenic disease

#276
20050059591
2005-03-17

Prevention and treatment of amyloidogenic disease

#277
20050053614
2005-03-10

Prevention and treatment of amyloidogenic disease

#278
20050049197
2005-03-03

Induction of immune response against desired determinants

#279
20050048646
2005-03-03

Method for inducing cytotoxic T lymphocyte

#280
20050048049
2005-03-03

Prevention and treatment of amyloidogenic disease

#281
20050037026
2005-02-17

Prevention and treatment of amyloidogenic disease

#282
20050031629
2005-02-10

Prevention and treatment of amyloidogenic disease

#283
20050019343
2005-01-27

Prevention and treatment of amyloidogenic disease

#284
20050019330
2005-01-27

Prevention and treatment of amyloidogenic disease

#285
20050019328
2005-01-27

Prevention and treatment of amyloidogenic disease

#286
20050013815
2005-01-20

Prevention and treatment of amyloidogenic disease

#287
20050009104
2005-01-13

Methods of attaching soluble HLA to solid supports

#288
20050003483
2005-01-06

Comparative ligand mapping from MHC class 1 positive cells

#289
9390061
2016-02-23

Inducing cellular immune responses to using peptide and nucleic acid compositions